ACUTE CORONARY SYNDROME IN PATIENTS WITH NORMAL LDL-C LEVELS: CLINICAL FEATURES AND POSSIBLE MECHANISMS

Authors

  • Abilov Pulat Melisovich Author
  • Akalayeva Diana Alfredovna Author

Keywords:

acute coronary syndrome, LDL-C, atherosclerosis, plaque instability, lipoprotein(a), apolipoprotein B, inflammation, cardiovascular risk.

Abstract

Acute coronary syndrome (ACS) is one of the major manifestations of coronary artery disease and remains an important cause of morbidity and mortality worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerosis and an important target of cardiovascular prevention. However, ACS can also occur in patients whose LDL-C concentration is not markedly elevated. This observation suggests that the development of ACS cannot always be explained by the current LDL-C level alone. The aim of this review is to summarize possible mechanisms of ACS in patients with apparently normal LDL-C and to describe the clinical factors that may contribute to cardiovascular risk in these patients. Particular attention is given to endothelial dysfunction, inflammation, plaque instability, lipoprotein(a), apolipoprotein B, triglyceride-rich lipoproteins, diabetes mellitus, hypertension, and smoking. Current evidence indicates that a normal LDL-C value does not necessarily mean a low lifetime exposure to atherogenic lipoproteins or the absence of coronary atherosclerosis. Additional lipid and clinical parameters may therefore be useful for a more complete assessment of cardiovascular risk. Understanding these mechanisms is important for the clinical evaluation and secondary prevention of patients with ACS.

References

1. Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025.

2. Blumenthal RS, Morris PB, Young J, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153:e1154-e1276.

3. Jia H, Abtahian F, Aguirre AD, et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol. 2013;62:1748-1758.

4. Libby P, Pasterkamp G. Requiem for the 'vulnerable plaque'. Eur Heart J. 2015;36:2984-2987.

5. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk: a systematic review. 2025. PMID: 40681368.

6. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. Eur Heart J. 2017;38:2459-2472.

7. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-1361.

8. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46:4359-4378.

9. Bian X, Zhang Y, Shao M, et al. Remnant cholesterol and risk of major adverse cardiovascular events: a systematic review and dose-response meta-analysis of cohort studies. Coron Artery Dis. 2024;35:413-421.

10. Impact of Lipoprotein(a) on Residual Cardiovascular Risk After an Acute Coronary Syndrome. J Clin Lipidol. 2026. PMID: 41827106.

Downloads

Published

2026-09-23